18 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Aug 2031. from the record

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

Ending by 2030

Aug 2031

Next term end

Patent families

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

202620272028202920302031203220332034 2035 2036 203720382039204020412042 2043 20442045

notable patents all others Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable: the highest-ranked patents in this portfolio by citations and family size.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Notable

Salt of a Pyrimido[6,1-a]isoquinolin-4-one Compound US 11,491,155

Cited by 10 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2036.

Ends Feb 2036 · High confidence Also notable

Liquid Inhalation Formulation Comprising RPL554 US 10,945,950

Cited by 12 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2035. A terminal disclaimer caps this term to an earlier patent's.

Ends Sep 2035 · High confidence Also notable

New Treatment US 10,864,213

Cited by 15 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2036.

Ends Aug 2036 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Mar 19, 2027
The maintenance fee for New Treatment (US 11,759,467) comes due Mar 19, 2027. Unpaid by Sep 20, 2027, it lapses early.
2 fees due May 5 to 12, 2027 · next May 5

Which patents, and when each one lapses · Pro

Recent changes

Sep 30Assignment recorded on US 9,062,047: Walker, Michael J.A. and 3 others to Verona Pharma PLC Recorded Sep 30, 2026, executed Feb 25, 2013. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76379, frame 500.
3 of the patents on this record were granted since Aug 17, 2026

What they patent

The 5 largest of its 12 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Particulate Composition	2 in force	to Jun 2044
Formulation Production Process	2 in force	to Feb 2043
New Treatment	2 in force	to Aug 2036
Salt of a Pyrimido[6,1-a]isoquinolin-4-one Compound	2 in force	to Feb 2036
Liquid Inhalation Formulation Comprising RPL554	2 in force	to Sep 2035

Patents held now

Soonest term end first.

Patent	Title	Status	Expires	Confidence
US 9,062,047	Crystalline Form of Pyrimido[6,1-a] ISOQUINOLIN-4-ONE Compound In force Term ends Aug 21, 2031 · High confidence	In force	Term ends Aug 21, 2031	High confidence
US 9,700,558	Drug Combination In force Term ends Mar 17, 2034 · High confidence	In force	Term ends Mar 17, 2034	High confidence
US 9,717,732	Drug Combination In force Term ends Mar 17, 2034 · High confidence	In force	Term ends Mar 17, 2034	High confidence
US 10,471,063	Drug Combination of PDE3/PDE4 Inhibitor and Muscarinic Receptor Antagonist In force Term ends Mar 17, 2034 · High confidence	In force	Term ends Mar 17, 2034	High confidence
US 9,956,171	Liquid Inhalation Formulation Comprising RPL554 In force Term ends Sep 15, 2035 · High confidence	In force	Term ends Sep 15, 2035	High confidence
US 10,945,950	Liquid Inhalation Formulation Comprising RPL554 In force Term ends Sep 15, 2035 · High confidence	In force	Term ends Sep 15, 2035	High confidence
US 11,759,467	New Treatment In force Term ends Dec 21, 2035 · High confidence	In force	Term ends Dec 21, 2035	High confidence
US 10,463,665	Salt of a Pyrimido[6,1-a]isoquinolin-4-one Compound In force Term ends Feb 10, 2036 · High confidence	In force	Term ends Feb 10, 2036	High confidence
US 11,491,155	Salt of a Pyrimido[6,1-a]isoquinolin-4-one Compound In force Term ends Feb 10, 2036 · High confidence	In force	Term ends Feb 10, 2036	High confidence
US 10,864,213	New Treatment In force Term ends Aug 22, 2036 · High confidence	In force	Term ends Aug 22, 2036	High confidence

10 of 18 patents shown.

Pro members see all 18.

Pro members: see all 18 patents

Also on record, not counted in the 18: 4 patents ended · 14 applications pending · 2 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built

Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Verona Pharma Limited